A Phase 1 Study of MORAb-202 in Subjects With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 30 Aug 2018
At a glance
- Drugs MORAb-202 (Primary)
- Indications Breast cancer; Endometrial cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Eisai Co Ltd
- 25 May 2018 Planned End Date changed from 1 Sep 2019 to 1 Sep 2020.
- 25 May 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.
- 04 Dec 2017 According to an Morphotek media release, first patient has been enrolled in the study.